AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9324434 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of D5W
Number of subjects: 28
Study 7706596 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT) diet for 30 days
Number of subjects: 5
Study 7706596 — intervention group
Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT) diet for 30 days
Number of subjects: 5
Study 7706596 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglycerides (MCT) diet
Number of subjects: 5
Study 7706596 — intervention group
Group type: COMPARATOR
Intervention: Long Chain Triglycerides (LCT) diet
Number of subjects: 5
Study 3661961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorenson Receptal Device (Group A)
Number of subjects: 50
Study 3661961 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion (Group H)
Number of subjects: 50
Study 29321125 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based safety decision aid (isafe)
Number of subjects: 412
Study 29321125 — intervention group
Group type: COMPARATOR
Intervention: Control website (standard, nonindividualized information)
Number of subjects: 412
Study 27591395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (n=19)
Number of subjects: 39
Study 27591395 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 39
Study 24615132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin treatment (once-treated communities)
Number of subjects: 24
Study 24615132 — intervention group
Group type: COMPARATOR
Intervention: Mass azithromycin treatment (twice-treated communities)
Number of subjects: 24
Study 23871267 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative OPG tertiles (low, medium, high)
Number of subjects: 124
Study 23871267 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative OPG levels
Number of subjects: 124
Study 23871267 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG levels
Number of subjects: 124
Study 23871267 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal LV systolic function
Number of subjects: 124
Study 23871267 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of filling pressure
Number of subjects: 124
Study 23871267 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class III or IV
Number of subjects: 124
Study 21186648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating magnetic field treatment
Number of subjects: 0
Study 21186648 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17765234 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 16
Study 17765234 — intervention group
Group type: COMPARATOR
Intervention: leuprolide acetate
Number of subjects: 16
Study 16641573 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMS-ORS (50g/L)
Number of subjects: 183
Study 16641573 — intervention group
Group type: COMPARATOR
Intervention: G-ORS (control)
Number of subjects: 183
Study 12962750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) with Cyclosporine (CyA) elimination at 3 months posttransplant
Number of subjects: 57
Study 12962750 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CyA) + Sirolimus (SRL)
Number of subjects: 57
Study 10885415 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathe Right (BR)
Number of subjects: 12
Study 10885415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8627205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aerosol (25, 50, or 100 mg bid for 12 weeks)
Number of subjects: 0
Study 8627205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1575223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure less than 30 mm Hg
Number of subjects: 162
Study 1575223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure between 30 and 39 mm Hg
Number of subjects: 162
Study 1575223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure between 40 and 49 mm Hg
Number of subjects: 162
Study 1575223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure between 50 and 59 mm Hg
Number of subjects: 162
Study 1575223 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraocular pressure more than 60 mm Hg
Number of subjects: 162
Study 1575223 — intervention group
Group type: EXPERIMENTAL
Intervention: High preoperative intraocular pressure
Number of subjects: 162
Study 3898416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined steroid and beta-stimulant preparation (salbutamol 100 micrograms/puff and beclomethasone dipropionate 50 micrograms/puff)
Number of subjects: 0
Study 3898416 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone (200 micrograms)
Number of subjects: 0
Study 30098982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior local treatment
Number of subjects: 0
Study 27528063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary flaxseed
Number of subjects: 62
Study 27528063 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma oxylipins
Number of subjects: 62
Study 24485587 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Cycloserine (50mg)
Number of subjects: 36
Study 24485587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23009891 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg ranibizumab monthly injections
Number of subjects: 1126
Study 23009891 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-mg ranibizumab monthly injections
Number of subjects: 1126
Study 23009891 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1126
Study 23009891 — intervention group
Group type: COMPARATOR
Intervention: PDT (verteporfin photodynamic therapy)
Number of subjects: 1126
Study 23009891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 1126
Study 20535923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose BVC (0.5 mg/kg)
Number of subjects: 36
Study 20535923 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose BVC (1.0 mg/kg)
Number of subjects: 36
Study 20535923 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 36
Study 18006170 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-month progressive resistance training (PRT) program (initial 2-month supervised, followed by 12-month maintenance)
Number of subjects: 28
Study 15705234 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/d wolfberry (estimated to contain almost 3 mg zeaxanthin) for 28 days
Number of subjects: 27
Study 15705234 — intervention group
Group type: COMPARATOR
Intervention: No wolfberry (control group)
Number of subjects: 27
Study 12849768 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with MSA
Number of subjects: 0
Study 12849768 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 12849768 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with MSA after initiation of the vertical lifting drive
Number of subjects: 0
Study 10534967 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) oxycodone (administered every 12 hours)
Number of subjects: 105
Study 10534967 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone (4 times a day)
Number of subjects: 105
Study 9345434 — intervention group
Group type: EXPERIMENTAL
Intervention: HTLV‐I synthetic peptide-stimulated peripheral blood lymphocytes (PBL) assay
Number of subjects: 20
Study 1675763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (400 mg per kilogram of body weight) every 28 days
Number of subjects: 372
Study 1675763 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 percent albumin) every 28 days
Number of subjects: 372
Study 1675763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 372
Study 1675763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 7148732 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 10
Study 7148732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet acidophilus milk
Number of subjects: 10
Study 7148732 — intervention group
Group type: COMPARATOR
Intervention: 2% milk, whole milk, skim milk, buttermilk
Number of subjects: 10
Study 30465314 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation sites with patient-reported outcomes and weight services
Number of subjects: 801
Study 30465314 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 801
Study 28457217 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with recurrent sialadenitis
Number of subjects: 40
Study 26842360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined microfinance and health leadership intervention for a period of two years.
Number of subjects: 1258
Study 26842360 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control arm).
Number of subjects: 1258
Study 24556982 — intervention group
Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC) for the first 24 hours, initiated between 30 minutes and 1 hour after birth.
Number of subjects: 100
Study 24556982 — intervention group
Group type: COMPARATOR
Intervention: Conventional care for the first 48 hours without SSC.
Number of subjects: 100
Study 24556982 — intervention group
Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC) for the first 24 hours.
Number of subjects: 100
Study 22383996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa+hazelnuts+phytosterols (2 g/d)
Number of subjects: 113
Study 22383996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d)
Number of subjects: 113
Study 22383996 — intervention group
Group type: COMPARATOR
Intervention: Cocoa cream (control)
Number of subjects: 113
Study 19384121 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent vaginal dinoprostone (3 mg pessary) and oxytocin infusion
Number of subjects: 114
Study 19384121 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion only (placebo)
Number of subjects: 114
Study 17463140 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT treatment group
Number of subjects: 60
Study 17463140 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 15047786 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps program for older volunteers
Number of subjects: 128
Study 15047786 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study 12506596 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 75
Study 12506596 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% propofol
Number of subjects: 75
Study 9576405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy for 6 months with targeted INR of 2.0 to 2.85
Number of subjects: 623
Study 9576405 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation therapy for 6 months
Number of subjects: 623
Study 9576405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy for 6 months or indefinitely
Number of subjects: 623
Study 9576405 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation therapy during the follow-up period
Number of subjects: 623
Study 7713766 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with 3 cycles of carboplatin/5-fluorouracil prior to surgery and radiotherapy (arm A)
Number of subjects: 97
Study 7713766 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with surgery and radiotherapy (arm B)
Number of subjects: 97
Study 2105793 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 42
Study 2105793 — intervention group
Group type: COMPARATOR
Intervention: Pituitary suppression with buserelin followed by pure follicle stimulating hormone
Number of subjects: 42
Study 2105793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 42
Study 2105793 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful pregnancies
Number of subjects: 42
Study 346430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 g per day)
Number of subjects: 24
Study 346430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30955400 — intervention group
Group type: EXPERIMENTAL
Intervention: lunasin-enriched soy extract (335mg/d)
Number of subjects: 31
Study 30955400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30517599 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 9296
Study 30517599 — intervention group
Group type: COMPARATOR
Intervention: Functional Activity Questionnaire (FAQ)
Number of subjects: 9296
Study 30517599 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA scores <21 or <22 (depending on education)
Number of subjects: 9296
Study 27384496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Bodies (intensive family-based obesity lifestyle intervention)
Number of subjects: 75
Study 27384496 — intervention group
Group type: COMPARATOR
Intervention: Clinic Care (routine outpatient Clinic Care)
Number of subjects: 75
Study 24670844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter-sparing surgery (SSS)
Number of subjects: 987
Study 24670844 — intervention group
Group type: COMPARATOR
Intervention: Abdominoperineal resection (APR)
Number of subjects: 987
Study 23663795 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training with a load of 40% of maximal inspiratory pressure, 5 sets of 10 breaths, twice a day, 7 days a week.
Number of subjects: 92
Study 23663795 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 92
Study 21779873 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3007
Study 21779873 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3007
Study 21779873 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3007
Study 21779873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3007
Study 18834309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study 17592683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 0
Study 17592683 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 16395633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fruit energy-restricted diet
Number of subjects: 15
Study 16395633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fruit energy-restricted diet
Number of subjects: 15
Study 16395633 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 15
Study 12518493 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental prototype powered toothbrush (Crest SpinBrush Pro)
Number of subjects: 70
Study 12518493 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available powered toothbrush (Crest SpinBrush)
Number of subjects: 70
Study 9805693 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane group (n = 13)
Number of subjects: 26
Study 9805693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane group (n = 13)
Number of subjects: 26
Study 8087515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (vindesine, cyclophosphamide, cisplatin, and lomustine) with a radiation dose of 65 Gy
Number of subjects: 353
Study 8087515 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone with a radiation dose of 65 Gy
Number of subjects: 353
Study 8087515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy
Number of subjects: 353
Study 8087515 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 353
Study 2790539 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1) at 1 mg/kg for 14 days then weekly for 12 weeks
Number of subjects: 15
Study 2790539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2790539 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (TP‐1)
Number of subjects: 15
Study 4633061 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly oral regimen of isoniazid plus PAS
Number of subjects: 247
Study 4633061 — intervention group
Group type: COMPARATOR
Intervention: Daily oral regimen of isoniazid plus PAS
Number of subjects: 247
Study 29172212 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 80 mg per day until the day of surgery (group 1)
Number of subjects: 206
Study 29172212 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) stopped 4 days before surgery (group 2)
Number of subjects: 206
Study 26002520 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted education intervention
Number of subjects: 3
Study 26002520 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 3
Study 23001939 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin-rich oil palm leaf extract (OPLE) 0.5 g day(‐1)
Number of subjects: 15
Study 21110694 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks of low-intensity norm duration hand rim wheelchair training, 3 times a week at 30% heart rate reserve (HRR) for 30 min
Number of subjects: 25
Study 21110694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study 18199182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonviolent resistance (NVR) training
Number of subjects: 73
Study 18199182 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 73
Study 17294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 1 mg/kg tramadol
Number of subjects: 45
Study 17294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 1 mg/kg meperidine
Number of subjects: 45
Study 17294997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 0.5 mg/kg ketamine
Number of subjects: 45
Study 12590905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 418
Study 12590905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 10377734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with interferon-alpha-2b (3 MU, three times a week) and ribavirin (1000-1200 mg daily) for one year
Number of subjects: 100
Study 10377734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with interferon-alpha-2b and ribavirin
Number of subjects: 100
Study 8927233 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (AMA) 100 mg, tid
Number of subjects: 42
Study 8927233 — intervention group
Group type: COMPARATOR
Intervention: Biperiden (BIP) 2 mg, tid
Number of subjects: 42
Study 1712193 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine 750 mg/day
Number of subjects: 10
Study 1712193 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide 600 mg/day
Number of subjects: 10
Study 7112396 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intralymphatic immunotherapy with MER-BCG, surgical excision with regional lymphadenectomy, and postoperative monthly intradermal vaccinations with BCG
Number of subjects: 25
Study 7112396 — intervention group
Group type: COMPARATOR
Intervention: Surgery and lymphadenectomy alone
Number of subjects: 25
Study 30522922 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) + cyclophosphamide (750 mg/m2) + doxorubicin (50 mg/m2) + prednisone (100 mg) (A+CHP)
Number of subjects: 452
Study 30522922 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (750 mg/m2) + doxorubicin (50 mg/m2) + vincristine (1.4 mg/m2) + prednisone (100 mg) (CHOP)
Number of subjects: 452
Study 29981285 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat + Lanthanum Carbonate
Number of subjects: 18
Study 29981285 — intervention group
Group type: COMPARATOR
Intervention: Roxadustat alone
Number of subjects: 18
Study 27716168 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 144
Study 27716168 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 144
Study 25106776 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey plus Coffee (HC)
Number of subjects: 75
Study 25106776 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Steroid (S)
Number of subjects: 75
Study 25106776 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (H)
Number of subjects: 75
Study 22186114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight-bound (TB) abdominal binding
Number of subjects: 13
Study 22186114 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose-bound (LB) abdominal binding
Number of subjects: 13
Study 22186114 — intervention group
Group type: COMPARATOR
Intervention: Unbound (UB) abdominal binding
Number of subjects: 13
Study 22186114 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied controls
Number of subjects: 13
Study 19282246 — intervention group
Group type: COMPARATOR
Intervention: Dementia-care mapping
Number of subjects: 289
Study 19282246 — intervention group
Group type: COMPARATOR
Intervention: Person-centred care
Number of subjects: 289
Study 19282246 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 289
Study 18003042 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (n=12)
Number of subjects: 30
Study 18003042 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 30
Study 16117818 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (50 U/kg, administered three times a week for 25 days)
Number of subjects: 30
Study 16117818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12191566 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg TNFR:Fc administered twice a week for 10 weeks
Number of subjects: 10
Study 10192108 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (enteric coated capsule containing 90 mg peppermint oil and 50 mg caraway oil)
Number of subjects: 223